Joshua Boger, Ph.D. is the founder of Vertex Pharmaceuticals, a biopharmaceutical company based in Boston. He has developed multiple drugs and is considered a pioneer in the field of structure-based rational drug design.
Dr. Boger founded Vertex in 1989, and he retired as CEO 20 years later in 2009. He continued to serve on the board until 2017, chairing its science and technology committee.
Before Vertex, he held the position of senior director of basic chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he led the departments of biophysical chemistry and medicinal chemistry of immunology and inflammation.
Dr. Boger launched his industry career at Merck, and during his tenure there, he developed a global reputation for the application of computer modeling to the chemistry of drug design and was a pioneer in the use of structure-based rational drug design as the basis for drug discovery programs. He is also known for setting up alliances between pharmaceutical companies and disease-focused foundations, resulting in the commercialization of the first drug to treat the genetic defect associated with cystic fibrosis.
Dr. Boger has also held the roles of executive chairman, board director, and chairman of the board for organizations including Bio (The Biotechnology Innovation Organization), Alkeus Pharmaceuticals, and Millennium Pharmaceuticals.
He is the author of more than 50 scientific publications and holds 32 U.S. patents in pharmaceutical development and discovery.
Dr. Boger is involved in multiple philanthropic efforts in the Boston area, focused on performing arts, science, social justice, and education. He sits on the boards of various organizations, including the Greater Boston Food Bank, the Boston Museum of Science, the Harvard Medical School board of fellows, and the Celebrity Series of Boston.
He earned his B.A. in chemistry and philosophy from Wesleyan University and his M.A. and Ph.D. in chemistry at Harvard University. Dr. Boger performed his postdoctoral research in molecular recognition in the laboratories of Nobel-prize winning chemist, Jean-Marie Lehn at the Université Louis Pasteur in Strasbourg, France.
What is Joshua S. Boger's net worth?
The estimated net worth of Joshua S. Boger is at least $112.75 million as of January 11th, 2017. Dr. Boger owns 276,225 shares of Vertex Pharmaceuticals stock worth more than $112,749,521 as of December 25th. This net worth evaluation does not reflect any other assets that Dr. Boger may own. Learn More about Joshua S. Boger's net worth.
How do I contact Joshua S. Boger?
Has Joshua S. Boger been buying or selling shares of Vertex Pharmaceuticals?
Joshua S. Boger has not been actively trading shares of Vertex Pharmaceuticals during the last quarter. Most recently, Joshua S. Boger sold 8,000 shares of the business's stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $82.48, for a transaction totalling $659,840.00. Following the completion of the sale, the director now directly owns 276,225 shares of the company's stock, valued at $22,783,038. Learn More on Joshua S. Boger's trading history.
Who are Vertex Pharmaceuticals' active insiders?
Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?
During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company.
Learn More about insider trades at Vertex Pharmaceuticals. Information on this page was last updated on 11/15/2024.